Cartesian Therapeutics, Inc.
RNAC
Classement en actions
#18142
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Prix de l'action
$6.44
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$194.84M
Changement (1 jour)
0.70%
Changement (1 an)
865.08%
Pays
US
Échange Cartesian Therapeutics, Inc. (RNAC)
Catégorie
Healthcare
Historique du prix de l'action pour Cartesian Therapeutics, Inc. (RNAC)
Prix de clôture le plus élevé : $0.79 le 2023-12-01
Prix de clôture le plus bas : $14.00 le 2016-06-01
Prix de clôture le plus bas : $14.00 le 2016-06-01
Historique du prix de l'action de Cartesian Therapeutics, Inc. de 2016 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $759.42 | 7.94% |
CH
|
